Ibtissem Oueslati
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ibtissem Oueslati has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
- Meriem Yazidi
Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia
39 shared publications M. Chihaoui
Service d’endocrinologie, hôpital La Rabta, Tunis, Tunisie
32 shared publicationsM. Yazidi
Service d’endocrinologie, hôpital La Rabta, Tunis, Tunisie
32 shared publications- Melika Chihaoui
Department of endocrinology, La Rabta University Hospital, Faculty of Medicine of Tunis, University of Tunis-El Manar, Tunis, Tunisia
30 shared publications F. Chaker
Service d’endocrinologie, hôpital La Rabta, Tunis, Tunisie
28 shared publicationsMelika Chihaoui
Department of Endocrinology University of Tunis el Manar, Faculty of Medicine of Tunis, La Rabta Hospital Tunis Tunisia
20 shared publications
Latest Publications
- 7 November 2026
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 25 (2) , 307
Bilateral pheochromocytoma and multiple paragangliomas in a patient with a heterozygous SDHD mutation: A challenging case report
- 7 November 2026
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 25 (2) , 307
Bilateral pheochromocytoma and multiple paragangliomas in a patient with a heterozygous SDHD mutation: A challenging case report
- 13 May 2026
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 25 (1) , 136
Health-related quality of life in women with hypopituitarism secondary to Sheehan syndrome: assessment and development of a new clinical score
Sheehan syndrome (SS) represents a rare cause of hypopituitarism. Data evaluating the quality of life (QoL) in women with SS are scarce. The aims of the present study were to evaluate the QoL in women with SS and to develop a clinical assessment score. This was a cross-sectional study including 62 women with hypopituitarism secondary to SS and 62 matched controls. QoL was evaluated using the 36-item Short Form Health Survey (SF-36). QoL was considered good if the SF-36 overall score was > 60. Factors associated with a good QoL were determined. A score including the factors associated with QoL was established and evaluated. Patients mean age 64 ± 8.9 years. The mean duration of the disease was 31.7 ± 8.5 years with a mean diagnosis delay of 9.6 ± 9.1 years. The QoL was good in 29% of patients and 52% of controls (p=0.029). Factors associated with a good QoL were the age ≤ 60 years (OR=4; p=0.021), gravidity≤ 3 (OR=14; p<0.001), parity ≤ 3 (OR=2; p<0.001), delay in diagnosis < 5 years (OR=4; p=0.021), duration< 30 years (OR=3; p=0.034), estroprogestative treatment (OR=3; p=0.030), good therapeutic compliance (OR=3; p=0.049), and absence of adrenal crisis during follow-up (OR=4; p=0.020). We developed a score as the sum of these parameters weighted by their respective ORs. The mean score was 26.9 ± 7.4 in the patients with good QoL compared to 12.1 ± 9.4 in patients with impaired QoL (p< 0.001).The score had an area under the ROC curve of 0.885 (p<0.001; 95% CI: 0.799-0.971). A score ≥ 21 was positively associated with a good QoL with an OR of 31.7 (p<0.001; 95% CI: 7-143.2), a sensitivity of 83% and a specificity of 86%. Women with hypopituitarism secondary to SS had significantly impaired QoL when compared to matched controls. The preliminary clinical score developed in this study may help assess QoL in women with Sheehan syndrome. Further validation in a larger sample size study is necessary to confirm its predictive value and facilitate its use in clinical practice.
- 13 May 2026
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 25 (1) , 136
Health-related quality of life in women with hypopituitarism secondary to Sheehan syndrome: assessment and development of a new clinical score
Sheehan syndrome (SS) represents a rare cause of hypopituitarism. Data evaluating the quality of life (QoL) in women with SS are scarce. The aims of the present study were to evaluate the QoL in women with SS and to develop a clinical assessment score. This was a cross-sectional study including 62 women with hypopituitarism secondary to SS and 62 matched controls. QoL was evaluated using the 36-item Short Form Health Survey (SF-36). QoL was considered good if the SF-36 overall score was > 60. Factors associated with a good QoL were determined. A score including the factors associated with QoL was established and evaluated. Patients mean age 64 ± 8.9 years. The mean duration of the disease was 31.7 ± 8.5 years with a mean diagnosis delay of 9.6 ± 9.1 years. The QoL was good in 29% of patients and 52% of controls (p=0.029). Factors associated with a good QoL were the age ≤ 60 years (OR=4; p=0.021), gravidity≤ 3 (OR=14; p<0.001), parity ≤ 3 (OR=2; p<0.001), delay in diagnosis < 5 years (OR=4; p=0.021), duration< 30 years (OR=3; p=0.034), estroprogestative treatment (OR=3; p=0.030), good therapeutic compliance (OR=3; p=0.049), and absence of adrenal crisis during follow-up (OR=4; p=0.020). We developed a score as the sum of these parameters weighted by their respective ORs. The mean score was 26.9 ± 7.4 in the patients with good QoL compared to 12.1 ± 9.4 in patients with impaired QoL (p< 0.001).The score had an area under the ROC curve of 0.885 (p<0.001; 95% CI: 0.799-0.971). A score ≥ 21 was positively associated with a good QoL with an OR of 31.7 (p<0.001; 95% CI: 7-143.2), a sensitivity of 83% and a specificity of 86%. Women with hypopituitarism secondary to SS had significantly impaired QoL when compared to matched controls. The preliminary clinical score developed in this study may help assess QoL in women with Sheehan syndrome. Further validation in a larger sample size study is necessary to confirm its predictive value and facilitate its use in clinical practice.
- Open Access
Lipid Profile in Primary Aldosteronism: Cross‐Sectional and Post‐Treatment Analyses
The relationship between primary aldosteronism (PA) and lipid metabolism remains controversial, with inconsistent findings reported in the literature. This study aimed to clarify PA's impact on the lipid profile using both a cross‐sectional comparison with essential hypertension (EH) controls and a longitudinal within‐patient pre‐post treatment analysis in a North African tertiary‐center cohort. This retrospective study included 112 patients with PA and 115 contemporaneously hospitalized patients with EH in whom secondary hypertension had been excluded. Sociodemographic, clinical, and biochemical variables (fasting blood glucose, HbA1c, lipid profile, creatinine, potassium, baseline aldosterone levels, and aldosterone‐to‐renin ratio), as well as therapeutic data, were collected at admission in both groups. In the PA group, clinical and biological parameters performed 1 year after specific PA management were recorded. Triglyceride levels were significantly higher in patients with PA not receiving lipid‐lowering therapy (1.47 (1.13–1.92) vs. 1.24 (1.02–1.69) mmol/L; p = 0.04) but this difference disappeared after multivariable adjustment for age, sex, BMI, and fasting glucose. A baseline aldosterone level > 200 pg/mL was associated with lower triglyceride levels (1.35 (1.02–1.81) vs. 1.81 (1.35–2.15) mmol/L; p = 0.01). Patients with PA who underwent adrenalectomy demonstrated a significant increase in triglyceride levels at 1 year (1.52 (1.32–2.11) vs. 2.08 (1.38–2.50) mmol/L; p = 0.04). The estimated glomerular filtration rate declined significantly 1 year after PA specific treatment (84.9 ± 19.7 vs. 73.6 ± 24.9 mL/min/1.73 m 2 ; p < 0.01). Our findings show mixed associations between aldosterone and triglyceride levels, which require confirmation in prospective studies.
Open AccessLipid Profile in Primary Aldosteronism: Cross‐Sectional and Post‐Treatment Analyses
The relationship between primary aldosteronism (PA) and lipid metabolism remains controversial, with inconsistent findings reported in the literature. This study aimed to clarify PA's impact on the lipid profile using both a cross‐sectional comparison with essential hypertension (EH) controls and a longitudinal within‐patient pre‐post treatment analysis in a North African tertiary‐center cohort. This retrospective study included 112 patients with PA and 115 contemporaneously hospitalized patients with EH in whom secondary hypertension had been excluded. Sociodemographic, clinical, and biochemical variables (fasting blood glucose, HbA1c, lipid profile, creatinine, potassium, baseline aldosterone levels, and aldosterone‐to‐renin ratio), as well as therapeutic data, were collected at admission in both groups. In the PA group, clinical and biological parameters performed 1 year after specific PA management were recorded. Triglyceride levels were significantly higher in patients with PA not receiving lipid‐lowering therapy (1.47 (1.13–1.92) vs. 1.24 (1.02–1.69) mmol/L; p = 0.04) but this difference disappeared after multivariable adjustment for age, sex, BMI, and fasting glucose. A baseline aldosterone level > 200 pg/mL was associated with lower triglyceride levels (1.35 (1.02–1.81) vs. 1.81 (1.35–2.15) mmol/L; p = 0.01). Patients with PA who underwent adrenalectomy demonstrated a significant increase in triglyceride levels at 1 year (1.52 (1.32–2.11) vs. 2.08 (1.38–2.50) mmol/L; p = 0.04). The estimated glomerular filtration rate declined significantly 1 year after PA specific treatment (84.9 ± 19.7 vs. 73.6 ± 24.9 mL/min/1.73 m 2 ; p < 0.01). Our findings show mixed associations between aldosterone and triglyceride levels, which require confirmation in prospective studies.
- 17 November 2025
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 87 (1) , 102470
Late-onset isolated corticotrophin deficiency induced by pembrolizumab in a patient with non-small-cell lung carcinoma
- 17 November 2025
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 87 (1) , 102470
Late-onset isolated corticotrophin deficiency induced by pembrolizumab in a patient with non-small-cell lung carcinoma
- 18 October 2025
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 49 (2) , 359-367
Hypoglycaemia and other risks of ramadan fasting in patients with primary adrenal insufficiency: A prospective controlled trial using 24-hour glucose monitoring
Background Patients with primary adrenal insufficiency (PAI) are at increased risk of hypoglycaemia and dehydration. We aimed to evaluate the risk of complications, particularly hypoglycaemia, associated with Ramadan fasting (RF) in patients with PAI, using continuous glucose monitoring (CGM). Methods In this prospective, randomised, crossover, case-control study, we evaluated the prevalence of complications using clinical, biological and CGM data during RF and non-fasting days in 30 patients with PAI. All participants were treated with hydrocortisone and fludrocortisone and received a therapeutic education. Results 27 women and 3 men, mean age: 44.8±9.2 years, median duration of PAI: 7 years (4-10.5). Median daily doses were 20 mg of hydrocortisone and 50 µg of fludrocortisone. The prevalence of complications was 67% during RF and 23% outside RF (p = 0.001). Eleven patients (37%) broke the fast due to the occurrence of a complication. Signs of hypoglycaemia were reported by 37% of the patients during RF and 3% outside fasting (p = 0.002). Mean interstitial glucose levels were lower during fasting than outside fasting. The prevalence of CGM-detected hypoglycaemia (71% vs. 63%, p = 1.000), time spent below 3.9 and 3.0 mmol/l, and blood pressure levels were not different between RF and non-fasting days. Urea levels increased during RF but remained within normal limits. Conclusion Complications were frequent during RF in patients with PAI. Hypoglycaemia was frequent both during and outside RF. Registered on Clinical Trials on February 28th, 2024, under the identifier NCT06299020.
- 18 October 2025
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 49 (2) , 359-367
Hypoglycaemia and other risks of ramadan fasting in patients with primary adrenal insufficiency: A prospective controlled trial using 24-hour glucose monitoring
Background Patients with primary adrenal insufficiency (PAI) are at increased risk of hypoglycaemia and dehydration. We aimed to evaluate the risk of complications, particularly hypoglycaemia, associated with Ramadan fasting (RF) in patients with PAI, using continuous glucose monitoring (CGM). Methods In this prospective, randomised, crossover, case-control study, we evaluated the prevalence of complications using clinical, biological and CGM data during RF and non-fasting days in 30 patients with PAI. All participants were treated with hydrocortisone and fludrocortisone and received a therapeutic education. Results 27 women and 3 men, mean age: 44.8±9.2 years, median duration of PAI: 7 years (4-10.5). Median daily doses were 20 mg of hydrocortisone and 50 µg of fludrocortisone. The prevalence of complications was 67% during RF and 23% outside RF (p = 0.001). Eleven patients (37%) broke the fast due to the occurrence of a complication. Signs of hypoglycaemia were reported by 37% of the patients during RF and 3% outside fasting (p = 0.002). Mean interstitial glucose levels were lower during fasting than outside fasting. The prevalence of CGM-detected hypoglycaemia (71% vs. 63%, p = 1.000), time spent below 3.9 and 3.0 mmol/l, and blood pressure levels were not different between RF and non-fasting days. Urea levels increased during RF but remained within normal limits. Conclusion Complications were frequent during RF in patients with PAI. Hypoglycaemia was frequent both during and outside RF. Registered on Clinical Trials on February 28th, 2024, under the identifier NCT06299020.
- Open Access
- 16 July 2025
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 13
Pheochromocytoma with two rare manifestations: Non-ST segment myocardial infarction with normal coronary arteries and blue toe syndrome
We present a 42-year-old man with acute coronary syndrome with normal coronary arteries and blue toe syndrome secondary to pheochromocytoma. The patient’s medical history included paroxysmal atrial fibrillation and severe hypertension. He complained of weight loss, headache, excessive sweating, palpitations, and anxiety. He had a dry gangrene on the extremity of the left big toe. Pheochromocytoma was confirmed by extremely elevated normetanephrine and metanephrine serum levels (40 and 61 times the upper limit of normal, respectively). Pheochromocytoma was confirmed. An abdominal computed tomography scan showed a voluminous left adrenal mass. Angio-computed tomography-scan of the lower extremities revealed normal arteries. The patient was treated with an alpha-adrenergic blocker, a beta-adrenergic blocker, and a calcium channel blocker. After discontinuation of the treatment by the patient, he presented with constrictive chest pain, blood pressure crisis, and palpitations. The diagnosis of non-ST segment elevation myocardial infarction was made. Coronary angiography revealed normal arteries. Antihypertensive treatment was reintroduced and a left adrenalectomy was performed without incidents. Ten days after surgery, blood pressure, heart rate, and electrocardiogram were normal. There was a significant improvement in the dry gangrene on the left big toe, 4 days after surgery. Pheochromocytoma may present with unusual clinical manifestations such as acute coronary syndrome and peripheral limb ischemia. Timely diagnosis and management of pheochromocytoma are crucial, as the manifestations in this case disappeared after the pheochromocytoma was surgically removed.
- 16 July 2025
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 13
Open AccessPheochromocytoma with two rare manifestations: Non-ST segment myocardial infarction with normal coronary arteries and blue toe syndrome
We present a 42-year-old man with acute coronary syndrome with normal coronary arteries and blue toe syndrome secondary to pheochromocytoma. The patient’s medical history included paroxysmal atrial fibrillation and severe hypertension. He complained of weight loss, headache, excessive sweating, palpitations, and anxiety. He had a dry gangrene on the extremity of the left big toe. Pheochromocytoma was confirmed by extremely elevated normetanephrine and metanephrine serum levels (40 and 61 times the upper limit of normal, respectively). Pheochromocytoma was confirmed. An abdominal computed tomography scan showed a voluminous left adrenal mass. Angio-computed tomography-scan of the lower extremities revealed normal arteries. The patient was treated with an alpha-adrenergic blocker, a beta-adrenergic blocker, and a calcium channel blocker. After discontinuation of the treatment by the patient, he presented with constrictive chest pain, blood pressure crisis, and palpitations. The diagnosis of non-ST segment elevation myocardial infarction was made. Coronary angiography revealed normal arteries. Antihypertensive treatment was reintroduced and a left adrenalectomy was performed without incidents. Ten days after surgery, blood pressure, heart rate, and electrocardiogram were normal. There was a significant improvement in the dry gangrene on the left big toe, 4 days after surgery. Pheochromocytoma may present with unusual clinical manifestations such as acute coronary syndrome and peripheral limb ischemia. Timely diagnosis and management of pheochromocytoma are crucial, as the manifestations in this case disappeared after the pheochromocytoma was surgically removed.
- 14 June 2025
- Published by Springer Nature in Endocrine
- Vol. 90 (1) , 166-171
Levothyroxine absorption test in patients with refractory hypothyroidism: how to interpret patient’s response to the test?
Introduction Levothyroxine (LT4) absorption test is indicated in patients with refractory hypothyroidism to distinguish between pseudo-malabsorption and malabsorption. However, this test is not standardized and its interpretation remains controversial. The aim of the present study was to evaluate the different interpretations of the LT4 absorption test to confirm or infirm a disorder of LT4 absorption in patients with refractory hypothyroidism. Methods This was a retrospective study including patients who were admitted for refractory hypothyroidism. LT4 absorption test was performed in all patients. Four different equations were used to interpret the test: The LT4 absorption rate, FT4 increment, FT4 increase rate, and FT4 ratio. Celiac disease serology and digestive endoscopy with biopsy were performed in all patients. Results Seven patients were enrolled in this study. Their median age was 38 years. The median duration of hypothyroidism was 2.6 years. The median dose of LT4 was 4 µg/kg/day. Before the LT4 absorption test, the median TSH and FT4 levels were 72.59 mIU/L and 0.52 ng/dL, respectively. Using LT4 absorption rate and FT4 ratio formulas, the test was consistent with the diagnosis of malabsorption in all patients. However, when using FT4 increase rate, four patients (P1, P2, P4, and P5) had malabsorption and three patients (P3, P6, and P7) had pseudo-malabsorption. According to the FT4 increment, six patients (P1, P2, P4, P5, P6, and P7) had malabsorption and one patient (P3) had pseudo-malabsorption. Etiological investigations revealed the presence of Helicobacter pylori gastritis in four patients (P1, P2, P4, and P5). Patients 3, 6, and 7 admitted non-compliance with LT4 treatment when confronted with evidence about pseudo-malabsorption. Conclusion The FT4 increase rate seemed more effective than LT4 absorption rate, FT4 ratio, and FT4 increment in differentiating pseudo-malabsorption from malabsorption. However, further multicenter studies involving larger sample sizes would be useful to confirm these findings.
- 14 June 2025
- Published by Springer Nature in Endocrine
- Vol. 90 (1) , 166-171
Levothyroxine absorption test in patients with refractory hypothyroidism: how to interpret patient’s response to the test?
Introduction Levothyroxine (LT4) absorption test is indicated in patients with refractory hypothyroidism to distinguish between pseudo-malabsorption and malabsorption. However, this test is not standardized and its interpretation remains controversial. The aim of the present study was to evaluate the different interpretations of the LT4 absorption test to confirm or infirm a disorder of LT4 absorption in patients with refractory hypothyroidism. Methods This was a retrospective study including patients who were admitted for refractory hypothyroidism. LT4 absorption test was performed in all patients. Four different equations were used to interpret the test: The LT4 absorption rate, FT4 increment, FT4 increase rate, and FT4 ratio. Celiac disease serology and digestive endoscopy with biopsy were performed in all patients. Results Seven patients were enrolled in this study. Their median age was 38 years. The median duration of hypothyroidism was 2.6 years. The median dose of LT4 was 4 µg/kg/day. Before the LT4 absorption test, the median TSH and FT4 levels were 72.59 mIU/L and 0.52 ng/dL, respectively. Using LT4 absorption rate and FT4 ratio formulas, the test was consistent with the diagnosis of malabsorption in all patients. However, when using FT4 increase rate, four patients (P1, P2, P4, and P5) had malabsorption and three patients (P3, P6, and P7) had pseudo-malabsorption. According to the FT4 increment, six patients (P1, P2, P4, P5, P6, and P7) had malabsorption and one patient (P3) had pseudo-malabsorption. Etiological investigations revealed the presence of Helicobacter pylori gastritis in four patients (P1, P2, P4, and P5). Patients 3, 6, and 7 admitted non-compliance with LT4 treatment when confronted with evidence about pseudo-malabsorption. Conclusion The FT4 increase rate seemed more effective than LT4 absorption rate, FT4 ratio, and FT4 increment in differentiating pseudo-malabsorption from malabsorption. However, further multicenter studies involving larger sample sizes would be useful to confirm these findings.
- Open Access
- 2 June 2025
- Published by Wiley in Clinical Endocrinology
- Vol. 103 (4) , 523-530
Ramadan Fasting Improves Health‐Related Quality of Life in Patients With Secondary Adrenal Insufficiency: A Prospective Interventional Case‐Control Study
Introduction: Intermittent fasting (IF) exposes patients with adrenal insufficiency (AI) to complications related to undertreatment. We aimed to determine the effect of IF during Ramadan on the quality of life of patients with secondary adrenal insufficiency (SAI) compared to healthy controls.Subjects and Methods: It is a prospective case‐control study conducted at the Department of Endocrinology of La Rabta University Hospital in Tunisia. Fifty patients with SAI and 100 age‐, sex‐ and body mass index‐matched controls were enrolled and followed up throughout Ramadan 2023. All participants answered the Addison's disease quality of life questionnaire (AddiQoL) before Ramadan and during the third week of fasting.Results: There were 33 women and 17 men, median age: 43 years (IQR: 34–55), median duration of SAI: 7.5 years (IQR: 4–12.5), treated with hydrocortisone at a median dose of 0.24 mg/kg/day (IQR: 0.20–0.27). Before Ramadan, there was no significant difference between patients and controls in the global AddiQoL score, fatigue score, and emotional sphere score (89 vs. 93, p = 0.196; 24 vs. 24, p = 0.354, and 24 vs. 25, p = 0.536, respectively). The score of AI symptoms was altered in patients (27 vs. 30, p = 0.021). During fasting, the global AddiQoL score (8.2% vs. 0%, p = 0.005), the fatigue score (8% vs. −1.7%, p = 0.003), the emotional sphere score (4.2% vs. 0%, p = 0.009), and the AI symptoms' score (9.1% vs. 0%, p = 0.017) improved in patients compared to controls.Conclusion: Ramadan fasting improved the quality of life in SAI patients by reducing fatigue, emotional stress, and AI symptoms.Trial Registration: Registered on ‘ClinicalTrials.gov’ under the identifier ID: NCT05827965.
- 2 June 2025
- Published by Wiley in Clinical Endocrinology
- Vol. 103 (4) , 523-530
Open AccessRamadan Fasting Improves Health‐Related Quality of Life in Patients With Secondary Adrenal Insufficiency: A Prospective Interventional Case‐Control Study
Introduction: Intermittent fasting (IF) exposes patients with adrenal insufficiency (AI) to complications related to undertreatment. We aimed to determine the effect of IF during Ramadan on the quality of life of patients with secondary adrenal insufficiency (SAI) compared to healthy controls.Subjects and Methods: It is a prospective case‐control study conducted at the Department of Endocrinology of La Rabta University Hospital in Tunisia. Fifty patients with SAI and 100 age‐, sex‐ and body mass index‐matched controls were enrolled and followed up throughout Ramadan 2023. All participants answered the Addison's disease quality of life questionnaire (AddiQoL) before Ramadan and during the third week of fasting.Results: There were 33 women and 17 men, median age: 43 years (IQR: 34–55), median duration of SAI: 7.5 years (IQR: 4–12.5), treated with hydrocortisone at a median dose of 0.24 mg/kg/day (IQR: 0.20–0.27). Before Ramadan, there was no significant difference between patients and controls in the global AddiQoL score, fatigue score, and emotional sphere score (89 vs. 93, p = 0.196; 24 vs. 24, p = 0.354, and 24 vs. 25, p = 0.536, respectively). The score of AI symptoms was altered in patients (27 vs. 30, p = 0.021). During fasting, the global AddiQoL score (8.2% vs. 0%, p = 0.005), the fatigue score (8% vs. −1.7%, p = 0.003), the emotional sphere score (4.2% vs. 0%, p = 0.009), and the AI symptoms' score (9.1% vs. 0%, p = 0.017) improved in patients compared to controls.Conclusion: Ramadan fasting improved the quality of life in SAI patients by reducing fatigue, emotional stress, and AI symptoms.Trial Registration: Registered on ‘ClinicalTrials.gov’ under the identifier ID: NCT05827965.